Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of spleen polypeptide for cancer-related fatigue in advanced malignancy
ChiCTR2000033608Phase 4Completed
- Sponsor
- Zhengzhou Third People's Hospital
- Start
- May 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of spleen polypeptide in cancer-related fatigue (CRF) (3 arms), sponsored by Zhengzhou Third People's Hospital. Primary endpoints: Cancer-related fatigue and Quality of life. Started May 2020; status: completed.
02
Drugs
spleen polypeptide
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on ChiCTR2000033608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033608.